In order to evaluate the survival predictive value of GPC6 and TMEM132D mRNA levels in early stage ovarian cancer, we performed a retrospective clinical analysis of the above-studied stage I-II ovarian cancer patients. This evidence concerns the gene TMEM132D and ovarian carcinoma.